Stratec Sells Its Way to a Better Margin — and Nobody Showed Up to Ask
A €44 million non-cash hit, a hematology business off 80%, and a conference call with zero questions: inside a small-cap reset that the tape may not yet price
SBS.DE · Earnings Call · 2026-11-12
A Call Nobody Attended
Stratec SE is a €352 million-market-cap diagnostics instrument maker. Its Q3 2026 call on 12 November opened with a confession: “It is not the AI market or a deepfake. I just have a minor head cold, so sorry for this voice.” — Marcus Wolfinger, CEO · 2026-11-12 That was the last moment of levity. Twenty-five minutes later the operator delivered the line that should frame this entire report: “there are no questions at this time.” — Operator · 2026-11-12 No analyst, no pushback, no scrutiny of a quarter in which the reported net result went negative and management simultaneously asked the market to re-underwrite the whole company on a "continuing operations" basis.
Silence is information. When a small-cap lobs a transformative divestiture into a market that doesn't bother to dial in, price discovery is deferred, not resolved.
The Divestiture Is the Quarter
The number that dominated the company's own keyword set this quarter was not a growth theme at all. valuation effect ranked first, and Diatron posted the largest momentum gain of any keyword in Stratec's twelve-quarter history. Diatron — the hematology and clinical chemistry subsidiary in Hungary, including US and Indian subsidiaries — was sold on the last day of October to a consortium of Indian investors for a €10 million fixed price plus earn-outs. The accounting consequence was a roughly €44 million non-cash write-down that dragged reported EPS to −€3.13.
The strategic logic is blunt and, to be fair, coherent: “we are giving up revenue, but we are removing a drag on earnings.” — Marcus Wolfinger, CEO · 2026-11-12 Diatron was expected to contribute around €20 million of 2026 sales against an adjusted EBIT of roughly negative €10 million. Management was even candid that this was less than the ~€30 million originally guided in early 2026 — the Diatron business simply deteriorated as the year ran. The hematology business came in roughly 80% below prior year, driven, per the CFO, by "1 specific product" rather than a market-wide collapse. And the CEO was careful to add that “it is not a clean break” — Marcus Wolfinger, CEO · 2026-11-12 — collaboration and future product cooperation continue.
The company then restated the world ex-Diatron: nine-month continuing-operations sales of €101.8 million, adjusted EBIT up from €17.2 million to €20.3 million, margin from 10.9% to 13.4%. That is the pitch — a structurally better margin on a smaller revenue base.
The Revenue Hole Nobody Interrogated
The flip side of the divestiture is that the headline group numbers were ugly. Nine-month revenue fell 5% at constant currency to €165 million, and that decline is not a rounding error. It splits into three parts. First, Diatron. Second, the service parts revenue shortfall, where management was unusually direct about cause and duration: one customer that “has undergone a change in ownership structure” — Tanja Bucherl, CFO · 2026-11-12, a decline that began in the second half of 2025 and continued into 2026. This is not treated as noise — it has been baked into the fourth-quarter outlook. Third, development and service revenue down around 7%, attributed to project timing.
The uncomfortable structure is the shape of the year. To hit the midpoint of the sales guidance, Q4 requires roughly €76 million — an extraordinarily end loaded finish, a pattern that has recurred so often in Stratec's history that the keyword has spiked in multiple prior quarters. Management guarded against optimism explicitly: “do not assume any recovery in service part sales compared with the 9 month run rate.” — Marcus Wolfinger, CEO · 2026-11-12 That is a CEO pre-emptively confessing that the service-parts customer hasn't bottomed.
What actually improved was cash. Operating cash flow swung from −€1.4 million to €39.4 million, free cash flow from −€14.8 million to €30.6 million, and net debt fell to €89 million from €112 million, giving 2.3x leverage. But the CFO was honest about the quality: “the main driver was actually the development in the working capital” — Tanja Bucherl, CFO · 2026-11-12 — specifically trade receivables falling from €56.9 million at year-end to €38.1 million, a release of an unusually back-end-loaded 2025. Cash release is real, but it's a collection event, not an earnings event.
What Management Stopped Saying
The most telling signal is in the vocabulary that vanished. The prior two quarters were dominated by life cycle management, lead time risk, obsolescence management and last-time buys. Those themes have dropped out of the top of this company's keyword set entirely — replaced by accounting and divestiture language. Some of that is simply that the analytical work is done; the redesign and revalidation pipeline that drove nine-month revenue is no longer the talking point.
But one absence is sharper. In both May and August, Marcus Wolfinger fielded questions about an expected compensation payment from a large German counterparty, with “arbitration ongoing” — Marcus Wolfinger, CEO · 2026-05-12 and settlement floated for the following year. That receivable — potentially meaningful against a €352 million market cap — was not mentioned once this quarter. Nor did the analyst base ask. Given the total silence on the Q&A, it simply evaporated from the narrative.
Equally worth flagging: the phrase of the year is now early stage development pipeline, elevated by the CEO to the single most important strategic priority — “filling the early stage development pipeline... remains paramount” — Marcus Wolfinger, CEO · 2026-11-12. A year ago the message was different in tone: “I wanted to get across that we believe that we are through the worst.” — Marcus Wolfinger, CEO · 2025-11-11 And when guidance was set, “I don't want to take a hit again” — Marcus Wolfinger, CEO · 2024-10-25 was the guiding principle. The company has since taken a revenue hit anyway — just while cleansing the P&L.
The Bet That Remains
The bull case is narrow and specific: core systems — molecular and immunoassay blood bank, complex sample prep — grew double digits in the nine months, newly developed systems are moving into early-stage series production, and the 13–15% adjusted EBIT margin guide for continuing operations (versus 8.3% reported for the nine months) reflects a genuinely different business. Rising accreditation requirements and regulatory fragmentation are, perversely, a tailwind for an outsourced instrument designer whose customers need more local, more compliant manufacturing.
What is not yet demonstrated: organic growth. Revenue at constant currency is guided only "stable to slightly higher" against pro-forma 2025 of €223.5 million. A margin story told on a shrinking top line, delivered to an audience that asked nothing, is a thesis waiting for its first real test — which is the 2027 launch cycle, not the fourth quarter.